12:00 AM
 | 
Jul 20, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Doxil doxorubicin regulatory update

FDA's Oncologic Drugs Advisory Committee voted 13-0 against expanding the label for Johnson & Johnson's Doxil doxorubicin to include use with docetaxel to treat advanced breast...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >